



Medicine Supply Notification

MSN/2022/086

Prochlorperazine (Stemetil®) 12.5mg/ml solution for injection ampoules

Tier 2 – medium impact*

Date of issue: 12/10/2022

Link: [Medicines Supply Tool](#)

Summary

- Prochlorperazine (Stemetil®) 12.5mg/ml solution for injection ampoules are out of stock until w/c 24th October 2022.
- Limited supplies remain available in NHS Trusts and health boards.
- Alternative anti-emetics remain available and are able to support an uplift in demand.

Actions Required

NHS Provider Trust Pharmacy Procurement teams should:

- review local stock holding of prochlorperazine 12.5mg/ml solution for injection ampoules, including stock being held at ward locations; and
- estimate if they hold sufficient stock to meet the anticipated demand until the re-supply date.

Where there are insufficient stocks, the organisation should:

- request mutual aid, facilitated by their Regional Pharmacy Procurement Specialist; or
- take immediate action and work with appropriate clinical leads and the local Medication Safety Officer (MSO) to review the use of prochlorperazine injection and switch to an alternative agent (see Supporting Information) ensuring:
 - impacted clinical areas are made aware of this shortage and local mitigations; and
 - prescribing systems, aid memoires or guidance documents are reviewed and updated as required.

Refer to BNF and local guidelines for choice of alternative antiemetic treatment options.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Prochlorperazine injection is licenced for the treatment of nausea and vomiting. It is one of several first line treatment options in hyperemesis gravidarum and is used as a rescue anti-emetic in post-operative nausea and vomiting. Refer to BNF and local treatment guidelines for alternative treatment options.

Please note in practice, prochlorperazine and alternative treatment options, are also used for off-label indications.

Please see the following links for further information:

[BNF: Nausea and labyrinth disorders](#)

[SmPC: Prochlorperazine 3mg buccal tablets](#)

[SmPC: Cyclizine Lactate 50mg/1ml solution for injection ampoules](#)

[SmPC: Metoclopramide 10mg/2ml solution for injection](#)

[SmPC: Ondansetron solution for injection ampoules](#)

Due to ongoing supply issues with Promethazine 25mg/ml solution for injection and Droperidol 2.5mg/ml solution for injection ampoules, these cannot support the gap in the market.

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Regional Pharmacy Procurement Specialist, who will escalate to national teams if required.

REGION	Full Name	Email
Midlands	Andi Swain (East Midlands)	andi.swain@nhs.net
	Diptyka Hart (West Midlands)	Diptyka.Hart@uhb.nhs.uk
East of England	James Kent	james.kent@nhs.net
London	Jackie Eastwood	jacqueline.eastwood@gstt.nhs.uk
North East and Yorkshire	David Allwood (Yorkshire)	davidallwood@nhs.net
North West	See Mun Wong	SeeMun.Wong@liverpoolft.nhs.uk
South East	Richard Bateman (South East Coast)	richard.bateman2@nhs.net
	Alison Ashman (Thames Valley & Wessex)	Alison.Ashman@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2022/083

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.